150 related articles for article (PubMed ID: 37614621)
21. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
[TBL] [Abstract][Full Text] [Related]
22. Rational Chemical Design of Molecular Glue Degraders.
Toriki ES; Papatzimas JW; Nishikawa K; Dovala D; Frank AO; Hesse MJ; Dankova D; Song JG; Bruce-Smythe M; Struble H; Garcia FJ; Brittain SM; Kile AC; McGregor LM; McKenna JM; Tallarico JA; Schirle M; Nomura DK
ACS Cent Sci; 2023 May; 9(5):915-926. PubMed ID: 37252349
[TBL] [Abstract][Full Text] [Related]
23. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
Diehl CJ; Ciulli A
Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
[TBL] [Abstract][Full Text] [Related]
24. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery.
Angers S; Li T; Yi X; MacCoss MJ; Moon RT; Zheng N
Nature; 2006 Oct; 443(7111):590-3. PubMed ID: 16964240
[TBL] [Abstract][Full Text] [Related]
25. Cullin-4A·DNA damage-binding protein 1 E3 ligase complex targets tumor suppressor RASSF1A for degradation during mitosis.
Jiang L; Rong R; Sheikh MS; Huang Y
J Biol Chem; 2011 Mar; 286(9):6971-8. PubMed ID: 21205828
[TBL] [Abstract][Full Text] [Related]
26. The Cullin 4A/B-DDB1-Cereblon E3 Ubiquitin Ligase Complex Mediates the Degradation of CLC-1 Chloride Channels.
Chen YA; Peng YJ; Hu MC; Huang JJ; Chien YC; Wu JT; Chen TY; Tang CY
Sci Rep; 2015 May; 5():10667. PubMed ID: 26021757
[TBL] [Abstract][Full Text] [Related]
27. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
28. Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead.
Nowak RP; Ragosta L; Huerta F; Liu H; Ficarro SB; Cruite JT; Metivier RJ; Donovan KA; Marto JA; Fischer ES; Zerfas BL; Jones LH
RSC Chem Biol; 2023 Nov; 4(11):906-912. PubMed ID: 37920397
[TBL] [Abstract][Full Text] [Related]
29. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage.
Hu J; McCall CM; Ohta T; Xiong Y
Nat Cell Biol; 2004 Oct; 6(10):1003-9. PubMed ID: 15448697
[TBL] [Abstract][Full Text] [Related]
30. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
31. DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras.
Zhang X; Luukkonen LM; Eissler CL; Crowley VM; Yamashita Y; Schafroth MA; Kikuchi S; Weinstein DS; Symons KT; Nordin BE; Rodriguez JL; Wucherpfennig TG; Bauer LG; Dix MM; Stamos D; Kinsella TM; Simon GM; Baltgalvis KA; Cravatt BF
J Am Chem Soc; 2021 Apr; 143(13):5141-5149. PubMed ID: 33783207
[TBL] [Abstract][Full Text] [Related]
32. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
33. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.
Hu Z; Crews CM
Chembiochem; 2022 Jan; 23(2):e202100270. PubMed ID: 34494353
[TBL] [Abstract][Full Text] [Related]
34. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
[TBL] [Abstract][Full Text] [Related]
35. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
[TBL] [Abstract][Full Text] [Related]
36. Cul4A and DDB1 associate with Skp2 to target p27Kip1 for proteolysis involving the COP9 signalosome.
Bondar T; Kalinina A; Khair L; Kopanja D; Nag A; Bagchi S; Raychaudhuri P
Mol Cell Biol; 2006 Apr; 26(7):2531-9. PubMed ID: 16537899
[TBL] [Abstract][Full Text] [Related]
37. Degradation of proteins by PROTACs and other strategies.
Wang Y; Jiang X; Feng F; Liu W; Sun H
Acta Pharm Sin B; 2020 Feb; 10(2):207-238. PubMed ID: 32082969
[TBL] [Abstract][Full Text] [Related]
38. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
Dann GP; Liu H; Nowak RP; Jones LH
Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
[TBL] [Abstract][Full Text] [Related]
39. The cullin 4B-based UV-damaged DNA-binding protein ligase binds to UV-damaged chromatin and ubiquitinates histone H2A.
Guerrero-Santoro J; Kapetanaki MG; Hsieh CL; Gorbachinsky I; Levine AS; Rapić-Otrin V
Cancer Res; 2008 Jul; 68(13):5014-22. PubMed ID: 18593899
[TBL] [Abstract][Full Text] [Related]
40. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
